When Dermatology Goes Systemic: Escalation, Monitoring, and the Cost of Going Deep
The skin is the one organ a drug can reach without ever entering the bloodstream. That single fact defines dermatology's great advantage — you can lay medicine directly on the diseased tissue and spare the rest of the body almost entirely. So the first question in every skin disease is not "which drug?" but "can I stay on the surface?" Most of the time the answer is yes. But there is a line — drawn by how much skin is involved, where it sits, and whether the patient will actually use the cream — beyond which you must send the drug through the whole body to reach the skin. Crossing that line trades a rash for a blood-test schedule, and understanding the trade is the whole of dermatologic prescribing.
A 34-year-old man has had plaque psoriasis for years — a few stubborn patches on his elbows and knees that a potent topical steroid and a vitamin-D analogue have always tamed. This winter is different. The plaques have marched across his trunk, his shins, his lower back; well over a tenth of his body is now red and scaling. He confesses he stopped applying the ointment weeks ago — greasy, tedious, and there was simply too much skin to cover twice a day. His scalp itches under thick scale that no cream seems to reach, and his fingernails are pitting and lifting. Nothing about his disease has changed its nature; it is the same psoriasis. But the arithmetic has changed. Too much surface, the wrong sites, and adherence that has quietly collapsed. He has crossed the line — and the next prescription will not be a cream but a drug that travels through his entire body, and a form for baseline blood tests.
Why topical is almost always the right first move
You are treating an organ you can literally see and touch. Most organs are locked away — to reach an inflamed joint or an irritable gut you must dose the whole bloodstream and accept exposure everywhere. The skin is the exception. Spread a drug on the surface and the diseased tissue sits in a high local concentration while systemic absorption stays low. This is the core pharmacokinetic gift of dermatology: a favourable therapeutic ratio at the target with minimal exposure to everything else. A potent topical corticosteroid on an eczema patch bathes the inflamed skin in enough drug to switch off the inflammation, yet almost none reaches the liver, the marrow, or the pituitary. The principle is the same one taught in the Principles of Pharmacology section — get the drug where it is needed and nowhere else — but the skin lets you achieve it more completely than almost any other route.
The topical toolkit is broad enough to cover most disease. Corticosteroids of graded potency are the workhorse anti-inflammatories. Calcineurin inhibitors (tacrolimus, pimecrolimus) are steroid-sparing options for the face and folds. Vitamin-D analogues (calcipotriol) calm the overactive keratinocyte in psoriasis. Retinoids (tretinoin, adapalene) and antimicrobials handle acne. Keratolytics such as salicylic acid lift scale. Each is chosen not only for its mechanism but for its vehicle — an ointment for dry lichenified skin, a cream for weeping areas, a gel or foam or lotion for hair-bearing scalp. Matching drug and vehicle to the lesion is a skill the Eczema and Psoriasis chapters develop in full.
Treating skin topically is like watering a single thirsty plant with a watering can: you pour exactly where it is needed and the rest of the garden stays dry. Going systemic is like turning on the sprinklers for the whole garden just to reach that one plant in the far corner — it works, but now every bed gets soaked whether it needed water or not. You only reach for the sprinklers when the dry patch is too big, too scattered, or too awkwardly placed for the watering can to reach. That is exactly the escalation decision in dermatology: the sprinklers water the liver, the kidneys, and the immune system too, which is why they come with gauges to watch.
Where the surface fails: the four triggers to escalate
Four things break the topical strategy — and every one of them appeared in the man on the couch. First, extent. Once disease covers a large body-surface area, applying cream twice daily becomes impractical, expensive, and — with potent steroids over wide areas — no longer even safe (more on that below). Second, severity: disease that is disabling, scarring, or refractory to correctly used topicals has declared that the surface is not enough. Third, site: some regions defeat topicals almost by anatomy. The scalp hides disease under hair and thick scale; nails are a sealed keratin box that creams cannot penetrate, so nail psoriasis or onychomycosis often needs an oral drug; and diseases with deep or mucosal involvement are simply out of a cream's reach. Fourth, adherence. A topical only works if it is used, and the daily grind of greasy, time-consuming application over large areas is one of the most under-recognized reasons "topical failure" is really application failure. A once-weekly tablet or an injection every few weeks can rescue an outcome that no cream, however good, was ever going to achieve in that patient's real life.
"Topical failure" deserves an autopsy before you escalate. Was the steroid potent enough for the site? Was enough applied — patients chronically under-dose, and the fingertip-unit rule exists precisely because "apply a thin layer" is routinely read as "apply almost nothing"? Was it used long enough, and was the diagnosis right? A patient labelled a topical failure who was in fact using a weak cream, sparingly, for two weeks, on the wrong diagnosis, has not failed topical therapy at all. Escalating such a patient to a systemic drug means accepting real systemic risk to solve a problem that better topical use would have fixed.
The surface is not a wall: systemic absorption of topicals
The clean line between "topical = local" and "systemic = whole body" is a useful teaching fiction, not a law of physics. Enough drug applied over enough skin becomes a systemic drug by the back door. The classic example is the potent or super-potent topical corticosteroid used over a large area, under occlusion, or on thin skin for weeks: enough is absorbed to suppress the hypothalamic-pituitary-adrenal axis — the very same HPA suppression taught in the Endocrine chapter for oral steroids. The patient's own adrenal glands wind down, and abruptly stopping the cream can precipitate an adrenal crisis, while the systemic load can also seed cushingoid features, glucose intolerance, and in children growth suppression. Percutaneous absorption is not fixed: it rises steeply with potency, surface area, occlusion (including nappies and skin folds), inflamed or broken skin, and the thin skin of the face, genitals, and infants. "It's only a cream" is a dangerous phrase.
- Topical therapy is the default because the skin lets you achieve a high local concentration with minimal systemic exposure.
- Escalate for one of four reasons: extent, severity, site (scalp/nails/deep), or collapsed adherence.
- Audit "topical failure" before escalating — potency, quantity, duration, and diagnosis are the usual culprits.
- Potent topical steroids over large or occluded areas ARE absorbed and can cause HPA-axis suppression.
- Absorption rises with potency, surface area, occlusion, broken skin, and thin skin (face, folds, infants).
- Going systemic trades a local rash for whole-body exposure — hence a monitoring schedule.
The systemic armamentarium — and its price tag in monitoring
Every systemic dermatology drug comes bundled with a surveillance plan; the drug and its blood tests are inseparable. Methotrexate, a folate-antagonist immunosuppressant, is a mainstay for severe psoriasis. Its dose-limiting toxicities are on the marrow and the liver, so it is tracked with a full blood count and liver function tests, and it is a potent teratogen requiring reliable contraception. Ciclosporin, a calcineurin inhibitor, works fast to control severe flares but is nephrotoxic and raises blood pressure, so blood pressure and renal function (creatinine) are the monitored parameters and its use is deliberately time-limited. Acitretin, an oral retinoid for psoriasis, drives up lipids and can strain the liver — so lipids and LFTs are watched — and it is profoundly teratogenic, with the added trap that it lingers in the body long after stopping, mandating years of pregnancy avoidance. Isotretinoin, the oral retinoid that can functionally cure severe acne, shares the retinoid signature — teratogenicity demanding a strict pregnancy-prevention programme, plus lipid and liver monitoring and the concept of a cumulative target dose rather than a fixed course. Methotrexate, ciclosporin, and the other immunosuppressants are taught in full in the Inflammation & Joints section, where the same agents treat rheumatoid disease; dermatology simply inherits them.
Beyond the classical agents sit the targeted biologics, monoclonal antibodies aimed at the precise cytokines that drive skin disease: TNF blockers, and the newer IL-17 and IL-23 inhibitors that have transformed severe psoriasis. Because they suppress a specific arm of immunity, their signature safety concern is infection — above all reactivating latent tuberculosis or hepatitis B. So the monitoring here shifts from routine bloods to pre-treatment screening: everyone is checked for latent TB and viral hepatitis before the first dose, because switching off that cytokine can wake a dormant infection. These biologics are the same class introduced in the Inflammation section. Newest of all are the oral JAK inhibitors, small molecules that block cytokine signalling inside the cell. They are effective across psoriasis, eczema, alopecia areata and vitiligo, but carry a distinctive warning cluster — dyslipidaemia, venous thromboembolism, and a class-wide caution about serious infection and malignancy — that shapes who is offered them and how they are watched.
Methotrexate → monitor FBC + LFTs; teratogenic. Ciclosporin → monitor BP + renal function (creatinine); time-limited. Acitretin → monitor lipids + LFTs; teratogenic and long-persisting. Isotretinoin → strict pregnancy-prevention programme + lipids/LFTs; cumulative-dose concept. Biologics (anti-TNF, anti-IL-17, anti-IL-23) → screen for latent TB + hepatitis B/C before starting; infection risk. JAK inhibitors (oral) → lipids, VTE risk, and boxed cautions on serious infection and malignancy. The unifying thread: name the drug and you must, in the same breath, name what it damages and how you will watch for it.
Two constraints that shadow everything: sun and pregnancy
Two themes recur across the whole systemic map and deserve to be named up front. The first is photoprotection. Many dermatologic drugs and therapies are photosensitizers or interact with ultraviolet light — retinoids, some antibiotics such as the tetracyclines used in acne, and phototherapy itself, where controlled UV is the treatment but its cumulative dose raises long-term skin-cancer risk. Strict sun protection is therefore not lifestyle advice bolted on at the end; it is part of the prescription. The second is pregnancy, which runs like a red thread through dermatologic prescribing. The retinoids (isotretinoin, acitretin) and methotrexate are among the most powerful teratogens in all of medicine, and the decision to use them in a person who can become pregnant is inseparable from a reliable contraception and pregnancy-prevention plan. In dermatology you rarely choose a systemic drug without first asking about sun exposure and pregnancy potential — they can veto an otherwise ideal agent.
- Each systemic drug is inseparable from its monitoring: name the agent, name the organ it threatens.
- Methotrexate (FBC/LFTs), ciclosporin (BP/renal), acitretin (lipids/LFTs) — three different surveillance profiles.
- Biologics need pre-treatment TB and hepatitis screening because immunosuppression can reactivate latent infection.
- JAK inhibitors carry lipid, VTE, infection, and malignancy cautions that shape patient selection.
- Photoprotection is part of the prescription for photosensitizers, retinoids, and phototherapy.
- Retinoids and methotrexate are major teratogens — pregnancy status can veto an otherwise ideal drug.
- Escalating to a systemic drug on a diagnosis of "topical failure" without checking potency, quantity, duration, and whether the diagnosis was even right.
- Treating potent topical steroids as risk-free — over large areas, under occlusion, or on infants they are absorbed enough to suppress the HPA axis.
- Prescribing a retinoid or methotrexate to someone who can become pregnant without a reliable contraception and pregnancy-prevention plan in place.
A patient with extensive severe psoriasis is about to start an IL-17 inhibitor. Before the first dose, which of the following is the single most important step?
- Topical is the default because the skin uniquely lets you achieve high local drug levels with minimal systemic exposure.
- Escalate to systemic therapy for extent, severity, resistant sites (scalp/nails/deep), or collapsed adherence — after auditing that the topical was actually used correctly.
- The topical/systemic line is porous: potent steroids over large or occluded areas are absorbed enough to suppress the HPA axis.
- Every systemic agent carries its own monitoring — methotrexate (FBC/LFTs), ciclosporin (BP/renal), retinoids (lipids/LFTs/teratogenicity), biologics (TB/hepatitis screening), JAK inhibitors (lipids/VTE/malignancy) — with photoprotection and pregnancy shadowing all of it.
- Rook's Textbook of Dermatology — Principles of topical and systemic therapy.
- Wolverton SE. Comprehensive Dermatologic Drug Therapy.
- British National Formulary (BNF) — Skin: topical corticosteroid potency and systemic immunosuppressants.
- NICE / British Association of Dermatologists (BAD) guidelines — Psoriasis: assessment and management (systemic and biologic therapy).
- Katzung BG. Basic & Clinical Pharmacology — Dermatologic pharmacology and corticosteroids.
- Menter A, et al. Joint AAD–NPF guidelines for the management of psoriasis with systemic and biologic agents.
